LAPOINTE ANTHONY GREGG

SEC source: 0001331860-26-000005 · form4-10132026_021014.xml · derivative · entry 6

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 192 shares

Expires 2032-11-16

SEC source: 0001331860-26-000005 · form4-10132026_021014.xml · derivative · entry 5

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 121 shares

Expires 2031-09-22

SEC source: 0001331860-26-000005 · form4-10132026_021014.xml · derivative · entry 4

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 63 shares

Expires 2030-09-15

SEC source: 0001331860-26-000005 · form4-10132026_021014.xml · derivative · entry 3

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 128 shares

Expires 2029-09-05

SEC source: 0001331860-26-000005 · form4-10132026_021014.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 74 shares

Expires 2028-09-26

SEC source: 0001331860-26-000005 · form4-10132026_021014.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 54 shares

Expires 2027-06-07

F1 · kind: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 632 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction.

SEC source: 0001331860-26-000003 · form4-09182026_080958.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,947

Underlying: Common Stock · 78,947 shares

Expires 2036-09-16

F1 · derivative.exercise_date: The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027.

SEC source: 0000905148-26-002532 · form4.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,250

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-26-000320 · form4.xml · derivative · entry 5

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,550 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000320 · form4.xml · derivative · entry 4

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,100 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000320 · form4.xml · derivative · entry 3

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,100 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000320 · form4.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,333 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000320 · form4.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,666 shares

Expires not disclosed

F1 · derivative.exercise_price: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

F1 · shares: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

SEC source: 0001415889-25-017870 · form4-06202025_080628.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,647

Underlying: Common Stock · 17,647 shares

Expires 2035-06-20

F1 · derivative.exercise_date: The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026.

SEC source: 0001104659-25-059034 · tm2517800-4_4seq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,550

Underlying: Common Stock · 26,550 shares

Expires 2035-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

SEC source: 0000905148-25-001933 · form4.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires 2035-05-23

F3 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-25-001933 · form4.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

SEC source: 0001415889-24-029300 · form4-12132024_091231.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,646

Underlying: Common Stock · 8,646 shares

Expires 2034-12-12

F1 · derivative.exercise_date: The stock option vests ratably on each of March 12, 2025, June 12, 2025, September 12, 2025 and December 12, 2025.

SEC source: 0001104659-24-069076 · tm2416582-7_4seq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,100

Underlying: Common Stock · 14,100 shares

Expires 2034-06-04

F1 · derivative.exercise_date: This option was granted on June 5, 2024 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

SEC source: 0000905148-24-001654 · form4.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-25

F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0000905148-24-001654 · form4.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0001415889-23-016526 · form4-12152023_041202.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,136

Underlying: Common Stock · 38,136 shares

Expires 2033-12-14

F1 · derivative.exercise_date: The stock option vests ratably on each of March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024.

SEC source: 0001104659-23-068342 · tm2317752-8_4seq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,100

Underlying: Common Stock · 14,100 shares

Expires 2033-06-01

F1 · derivative.exercise_date: This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

SEC source: 0001140361-23-034286 · form4.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-05-26

F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0001140361-23-034286 · form4.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0001415889-22-011629 · form4-11212022_091111.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,747

Underlying: Common Stock · 46,154 shares

Expires 2032-11-16

F1 · derivative.exercise_date: The stock option vests ratably on each of February 17, 2023, May 17, 2023, August 17, 2023 and November 17, 2023.

SEC source: 0001104659-22-069754 · tm2218033-2_4seq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,333

Underlying: Common Stock · 8,333 shares

Expires 2032-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

SEC source: 0001104659-22-072749 · tm2218796-2_4aseq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,333

Underlying: Common Stock · 8,333 shares

Expires 2032-06-08

F1 · derivative.exercise_price: This amendment is being made to show the correct price of $3.00. An incorrect price of $2.99 was previously reported.

F2 · derivative.exercise_date: This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

SEC source: 0001140361-22-020306 · form4.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-05-20

F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0001140361-22-020306 · form4.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

SEC source: 0001104659-21-119309 · tm2128426-2_4seq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,126

Underlying: Common Stock · 29,126 shares

Expires 2031-09-22

F1 · security: The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022.

F1 · derivative.exercise_date: The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022.

SEC source: 0001104659-21-075899 · tm2118270-2_4seq1.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-06-01

F1 · derivative.exercise_date: This option was granted on June 2, 2021 and is schedule to vest in equal annual installments over a three-year period from the date of grant, subject to the director's continued service.

SEC source: 0001179110-21-005766 · edgar.xml · derivative · entry 2

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-05-19

F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

SEC source: 0001179110-21-005766 · edgar.xml · nonDerivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors.

SEC source: 0001213900-20-027374 · ownership.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,228

Underlying: Common Stock · 15,228 shares

Expires 2030-09-15

F1 · security: The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021.

F1 · derivative.exercise_date: The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021.

SEC source: 0001104659-20-072735 · a4.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest in full on June 11, 2021.

SEC source: 0001179110-20-006132 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-05-15

F1 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

SEC source: 0001213900-19-017650 · ownership.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,928

Underlying: Common Stock · 30,928 shares

Expires 2029-09-05

F1 · security: The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020.

F1 · derivative.exercise_date: The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020.

SEC source: 0001179110-19-006699 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2029-05-23

F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

SEC source: 0001179110-19-001939 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,200

Underlying: Common Stock · 12,200 shares

Expires 2029-02-12

F1 · derivative.exercise_date: This option was granted on February 13, 2019. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversay of the grant date until the third anniversary of the grant date.

SEC source: 0001179110-19-000404 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,800

Underlying: Common Stock · 2,800 shares

Expires 2029-01-02

F1 · derivative.exercise_price: This 4/A is being filed to correct the stated Conversion or Exercise Price of Derivative Security. The correct Exercise Price of the Derivative Security is $4.60 and was previously stated at $4.90.

F2 · derivative.exercise_date: This option was granted on January 3, 2019. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversary of the grant date until the third anniversary of the grant date.

SEC source: 0001179110-19-000343 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,800

Underlying: Common Stock · 2,800 shares

Expires 2029-01-02

F1 · derivative.exercise_date: This option was granted on January 3, 2019. The option is scheduled to vest as to one-third of the shares of common stock underlying the option on each anniversay of the grant date until the third anniversay of the grant date.

SEC source: 0001213900-18-013223 · ownership.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,964

Underlying: Common Stock · 17,964 shares

Expires 2028-09-26

F1 · security: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019.

F1 · derivative.exercise_date: The stock option vests ratably on each of December 27, 2018, March 27, 2019, June 27, 2019 and September 27, 2019.

SEC source: 0001179110-18-007150 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2028-05-17

F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

SEC source: 0001179110-17-013684 · edgar.xml · derivative · entry 1

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2027-10-31

F1 · derivative.exercise_date: The Option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services.

SEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 9

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2027-06-08

F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F10 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger.

SEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 8

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2025-06-11

F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F9 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.

SEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 7

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2024-06-12

F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F8 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015.

SEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 6

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2023-06-27

F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F7 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014.

SEC source: 0000899243-17-024255 · doc4.xml · derivative · entry 5

LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2022-06-07

F2 · price: The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.

F6 · derivative.exercise_date: Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013.